Athira Pharma, Inc.
ATHA
$0.295
-$0.008-2.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.53% | -18.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.74% | -38.94% | |||
| Operating Income | 38.74% | 38.94% | |||
| Income Before Tax | 39.06% | 47.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 39.06% | 47.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.06% | 47.80% | |||
| EBIT | 38.74% | 38.94% | |||
| EBITDA | 39.35% | 39.32% | |||
| EPS Basic | 39.58% | 48.06% | |||
| Normalized Basic EPS | 39.27% | 39.23% | |||
| EPS Diluted | 39.58% | 48.06% | |||
| Normalized Diluted EPS | 39.27% | 39.23% | |||
| Average Basic Shares Outstanding | 0.88% | 0.48% | |||
| Average Diluted Shares Outstanding | 0.88% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||